GWS
BMRN icon

Glassman Wealth Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Glassman Wealth Services’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-43
Closed -$4.15K – 424
2023
Q4 		$4.15K Sell
43
-160
-79% -$14.2K ﹤0.01% 1131
2023
Q3 		$18K Sell
203
-62
-23% -$5.52K ﹤0.01% 679
2023
Q2 		$23K Buy
265
+1
+0.4% +$94 ﹤0.01% 589
2023
Q1 		$25.7K Buy
264
+8
+3% +$829 ﹤0.01% 576
2022
Q4 		$26.5K Buy
256
+9
+4% +$845 ﹤0.01% 590
2022
Q3 		$21K Hold
247
– – ﹤0.01% 598
2022
Q2 		$20K Sell
247
-87
-26% -$6.93K ﹤0.01% 616
2022
Q1 		$26K Buy
334
+58
+21% +$4.85K ﹤0.01% 564
2021
Q4 		$24K Buy
276
+31
+13% +$2.56K ﹤0.01% 558
2021
Q3 		$19K Buy
245
+15
+7% +$1.18K ﹤0.01% 590
2021
Q2 		$19K Buy
230
+6
+3% +$476 ﹤0.01% 584
2021
Q1 		$17K Buy
224
+2
+0.9% +$163 ﹤0.01% 568
2020
Q4 		$19K Buy
222
+196
+754% +$15.5K ﹤0.01% 539
2020
Q3 		$2K Sell
26
-67
-72% -$6.78K ﹤0.01% 966
2020
Q2 		$11K Buy
93
+67
+258% +$6.66K ﹤0.01% 468
2020
Q1 		$2K Buy
26
+18
+225% +$1.55K ﹤0.01% 677
2019
Q4 		$1K Buy
+8
New +$604 ﹤0.01% 862
2019
Q3 		– Sell
-50
Closed -$4K – 1066
2019
Q2 		$4K Sell
50
-6
-11% -$513 ﹤0.01% 573
2019
Q1 		$5K Buy
56
+48
+600% +$4.45K ﹤0.01% 535
2018
Q4 		$1K Hold
8
– – ﹤0.01% 604
2018
Q3 		$1K Hold
8
– – ﹤0.01% 652
2018
Q2 		$1K Buy
8
+4
+100% +$350 ﹤0.01% 627
2018
Q1 		$0 Buy
+4
New +$343 ﹤0.01% 751

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Glassman Wealth Services's BMRN Position: Q1 2024 in Review

Glassman Wealth Services sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 43 shares — an estimated $4.15K sold.

Glassman Wealth Services first reported a position in BMRN in Q1 2018 and held it in 23 quarters. The position peaked at $26.5K in Q4 2022. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Glassman Wealth Services reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 43 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $4.15K.
  • Glassman Wealth Services first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 23 quarters.
  • Glassman Wealth Services's BioMarin Pharmaceuticals position peaked at $26.5K in Q4 2022.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.